durvalumab + AZD4547

**Durvalumab + AZD4547** is an investigational combination therapy consisting of **durvalumab**, a monoclonal antibody targeting programmed death-ligand 1 (**PD-L1**), and **AZD4547**, a potent and selective small molecule inhibitor of **fibroblast growth factor receptor 1, 2, and 3 tyrosine kinases (FGFR1/2/3)**. Durvalumab acts as an immune checkpoint inhibitor, blocking PD-L1's interactions with PD-1 and CD80 to enhance T cell-mediated anti-tumor responses[5][7]. AZD4547 inhibits aberrant FGFR signaling, which is implicated in tumorigenesis in cancers with FGFR mutations, fusions, or amplifications[1][4]. This combination is being studied primarily for advanced cancers, including bladder cancer and urothelial carcinoma with FGFR pathway alterations[1][5][3].

Brand names

Imfinzi

Other names

durvalumabAZD4547AZD-4547AZD 4547MEDI4736MEDI-4736MEDI 4736